EyePoint Pharmaceuticals (EYPT) H.C. Wainwright 4th Annual Ophthalmology Virtual Conference summary

Conference overview

• H.C. Wainwright hosted its fourth annual Ophthalmology Virtual Conference, featuring panels and presentations from industry leaders.

• The event included live-streamed panels and access to presentations via an online portal.

Company and pipeline highlights

• DURAVYU (vorolanib intravitreal insert) is the lead asset, targeting wet AMD and DME, with phase III trials imminent.

• Pipeline includes EYP-2301 (razuprotafib, a Tie2 agonist) and a complement inhibition program, both using Durasert E sustained-release technology.

• $280 million in cash and investments as of June 30, 2024.

DURAVYU technology and mechanism

• Durasert E enables sustained, bio-erodible drug delivery for up to nine months, administered via standard intravitreal injection.

• Vorolanib is a pan-VEGF receptor inhibitor, also blocking PDGF, potentially reducing fibrosis in wet AMD.

• The insert is stable at ambient temperature and does not require refrigeration.